

Hemophilic Arthropathy: Basic Records for Proper Joint and Musculoskeletal Health Care in Patients with Hemophilia

Querol-Giner F, Perez-Alenda S and Querol-Fuentes F*

Physiotherapy Department, University of Valencia, Spain

ARTICLE INFO

Received Date: July 20, 2020
Accepted Date: August 16, 2020
Published Date: August 20, 2020

KEYWORDS

Haemophilia care
Hemophilic arthropathy
Health joint

Copyright: © 2020 Querol-Fuentes F et al., SL Clinical Medicine: Research. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation for this article: Querol-Giner F, Perez-Alenda S and Querol-Fuentes F. Hemophilic Arthropathy: Basic Records for Proper Joint and Musculoskeletal Health Care in Patients with Hemophilia. SL Clinical Medicine: Research. 2020; 3(1):118

Corresponding author:

Felipe Querol Fuentes,
Physiotherapy Department, University of Valencia, C / Gasc Oliag N 3, 46010 Valencia, Spain, Tel: +34 963983853;
Email: Felipe.Querol@uv.es

ABSTRACT

Hemophilia is a genetic disease, classified as a rare disease and affects approximately 1 in every 5,000 live births male. It is classified as severe, moderate and mild depending on the percentages of plasma circulating coagulation factors. It is characterized by hemorrhagic episodes that, in the absence of treatment, occur spontaneously in muscles and joints, causing hemophilic arthropathy and greatly influencing quality of life.

Joint health care in the hemophilia patient involves, in addition to factor replacement therapy, very strict monitoring to detect early signs of the joint degenerative process caused by even subclinical hemorrhages.

The World Federation of Haemophilia establishes health recommendations that include the use of specific forms for clinical and radiological evaluation that allow the evolutionary control of the disease.

The objective of this work is the description of the medical care that patients receive or should receive and the universal use forms that allow the control of joint health.

It concludes by pointing out the importance of care and the unification of criteria for the evolutionary control of the disease.

INTRODUCTION

Hemophilia is a genetic coagulation disorder that continues to affect approximately 1 in 5,000 live births and is characterized by bleeding involving the musculoskeletal system with serious implications for physical activity and quality of life [1-4].

Two realities directly related to joint health are identified in hemophilia in today's world: 1) populations of hemophilia (PWH) patients who have access to factor replacement therapy and 2) those who do not have adequate hematological treatment. In both populations, musculoskeletal disorders are the most frequent and limiting daily life activities and quality of life.

There are also two health care needs for the patient with hemophilia:

- 1) The first need, for the evolutionary control of the disease, the provision of regulated assistance in medical consultation in Haemophilia Centers by multidisciplinary teams led by hematologists.
- 2) And the second need, the possibility of early care after an acute bleeding episode.

Some tools, although with specific interest in the pharmacokinetics of coagulation factors, also monitor acute bleeding processes and physical activity, some examples

are: FlorioTM, WAPPS Hemo (Population Pharmacokinetic Service accessible on the web - Hemophilia), Haemoassist® and MyPKFiT™ [5-7].

Considering, as a minimum, the inevitable possibility of accidental musculoskeletal injuries, hemarthrosis and muscular hematomas, which mainly lead to hemophilic arthropathy, the objective of this work is to show care protocols that affect the criteria of joint health care.

The following section describes the specific data that is recorded and is summarized on specific forms. The results and conclusions of the use of unified forms are obvious, since they have useful records for health control.

BASIC RECORDS, FORMS AND SCORES

First, we consider the attention in consultation and the two possibilities that represent the need of the patient with hemophilia.

Attention in medical consultation

Attendance at the hospital or point of care of the patient with hemophilia can only be for two reasons:

- 1) An acute bleeding problem (Figure 1) or
- 2) The systematic clinical review program (1 or 2 times a year in severe hemophilia) for the global evolutionary control of the disease. In either case, a minimum data protocol to be recorded must be considered [8].

The minimum data collected for the consideration of clinical discharge from hemarthrosis are shown in Table 1 and the Table 2 shows, briefly, the items to register, the concept and the details (Table 1).



Figure 1: Acute hemorrhagic process: clinical evaluation of the ROM, swelling and evaluation by radiological, echographic and MR images.

Table 1: Data recorded for the evolutionary control of hemarthrosis and the consideration and score 0 points equivalent to the normality and resolution of the acute process.

| | |
|---|---|
| Pain: | 0: NO |
| Swelling | 0: Not observed |
| Active ROM without pain: | 0: Value in degrees without discomfort equal to degrees as in the state prior to hemarthrosis |
| Effort / walking without pain: | 0: As in the situation before the problem |
| Discharged from acute process by echography: | Return to PREVIOUS SITUATION or CHRONICITY CONSIDERATION (of the new image) with the requirement of a new SCORE (HEAD-US) |

Table 2: Basic concepts of a standard program, which target the musculoskeletal health of the hemophilia patient.

| Items | Concepts | Details |
|--|--|---|
| Date | Of the current visit | To establish control |
| Review period | Date of the last routine check-up | It is essential to know the number of bleeding episodes that occurred in the period |
| Routine check | The existence or absence of musculoskeletal problems with factor requirements is noted in the period since the last routine review visit | Problems (if any) in the joints or areas where they have existed are detailed |
| Hemophilia type and severity | A or B and severe, moderate or mild | It is common to highlight this, as well as verify the type of commercial factor that is used |
| Treatment modality | On demand or prophylaxis | The dose and frequency are usually indicated. |
| Data last factor administration | Dose, date and time | Essential in severe hemophilia to safely perform exploratory maneuvers |
| Current size and weight | Control of obesity | Important for measuring body mass index and dietary and physical activity recommendations |
| Physical activity | Minimum: sedentary or active | Use of forms is recommended, for example FISH (Functional Independence Score in Hemophilia), IPAQ short version (International Physical Activity Questionnaire) |
| Sport | If you do it regularly and what | Frequency of sports practice |
| Clinical score | Date | Score type (HJHS, Gilbert, etc.) and its global score |
| Score Rx | Last date (if available) | Pettersson score (global score of the 6 key joints) |
| Ultrasound score | Date | HEAD-US or basic protocol of ultrasound normality yes or no |
| Score MR | Last date (if available) | Denver score or at least indicate the presence / absence of injury |
| Densitometry | Date (if available) | At a minimum note normality, osteopenia or osteoporosis |

Regarding the medical review and specifically related to joint and musculoskeletal health, the data is recorded by a physical therapist or a doctor specializing in rehabilitation and physical medicine. A basic summary of the

records in the medical record is shown in Table 2, and the forms / scores recommended by the World Federation of Hemophilia (WFH) are described below (Table 2).

Some centers use graphic forms that provide a summary of each joint and a visual impression of the joint overall. Figure 2 shows the annual revision form used by the Hemostasis and Thrombosis Unit of the LA FE Polytechnic and University Hospital in Valencia (Spain) [9] (Figure 2).

ANNUAL REVIEW SHEET

Biographical data:
SURNAMES
 Name
 Birth date

Date of visit: ___/___/___
*T*Size: ___ cm. *W*eight: ___ Kg.

| | |
|---|---------------------------------------|
| Date of last administration factor: ___/___/___ | Location of the last bleeding episode |
| Last visit date (LVD): ___/___/___ | Date of last bleeding episode: |
| Factor consumption from LVD until today: UI | |

| | |
|--|---|
| Hemophilia type (A or B): | |
| <i>Treatment modality: Emulsió / Desnat.</i> | |
| Factor: | TOTAL factor consumption (during the period) UI |

Mark **X** affected joints

| | ELBOWS | | KNEES | | ANKLES | | | | | |
|--|--------|---|-------|---|--------|---|---|---|---|---|
| | R | L | R | L | R | L | R | L | R | L |
| Total hemarthrosis (historical) | | | | | | | | | | |
| Score* | | | | | | | | | | |
| Number hemartros period | | | | | | | | | | |
| Number haematomas | | | | | | | | | | |
| ARTROPATIA CLINICA | | | | | | | | | | |
| Present (Yes: 1 /No: 0) in: | | | | | | | | | | |
| Score (1) Date: | | | | | | | | | | |
| Rx convencional | | | | | | | | | | |
| Present (Yes: 1 /No: 0) in: | | | | | | | | | | |
| Score (2) Date: | | | | | | | | | | |
| ARTROPATIA RMN | | | | | | | | | | |
| Present (Yes: 1 /No: 0) in: | | | | | | | | | | |
| Score (3) Date: | | | | | | | | | | |
| ALTERACIÓN ECOGRÁFICA | | | | | | | | | | |
| (4) Date: ___/___/___ | | | | | | | | | | |
| Effusion (Yes / No) in: | | | | | | | | | | |
| Structural alteration (Yes: 1/No: 0) in | | | | | | | | | | |
| (5) Score HEAD-US (Arthropathy) Date: | | | | | | | | | | |
| DENSITOMETRIA | | | | | | | | | | |
| Is it altered? NO: 0 Yes: 1: osteopenia; 2: osteoporosis | | | | | | | | | | |
| Date: ___/___/___ | | | | | | | | | | |

*) **Total historical hemarthrosis score in each joint (0= 0; 1= 1-3; 2=4-6; 3=7-9; 4=>10)**

- Clinical score if available (**Gilbert score**, Gilbert MS. *Semin Hematol* 1993; 30:3-6; or **HUSJ 2.1** of World Federation of Hemophilia: http://www1.wfh.org/docs/en/Publications/Assessment_Tools/HUSJ_Summary_Score.pdf)
- Radiological score if available (**Pettersson score**, Pettersson H, et al. *Clin Orthop Relat Res* 1980; 149: 153-9)
- MRI score if available (**Denver score**, **Nuss R**, et al. *Haemophilia* 2000; 6: 658-63)
- Evaluación de la presencia de efusión (Implica tratamiento presumible proceso agudo) y anomalía estructural en tejidos (proceso crónico implica artropatía)
- Evaluación de signos precoces de artropatía acorde a Score ecográfico (si se dispone de la evaluación)

Observations:

Figure 2: Form that summarizes the basic data of the annual musculoskeletal clinical review in the Haemostasis and Thrombosis Unit (La Fe Hospital, Valencia – Spain).

03

Hemophilic Arthropathy: Basic Records for Proper Joint and Musculoskeletal Health Care in Patients with Hemophilia. SL Clinical Medicine: Research. 2020; 3(1):118.

Subject ID #: _____ Name of Physiotherapist: _____

Assessment # : _____ Date: _____
 Time: _____ yyyy / mm / dd

Hemophilia Joint Health Score 2.1 - Summary Score Sheet

| | Left Elbow | Right Elbow | Left Knee | Right Knee | Left Ankle | Right Ankle |
|---------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Swelling | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE |
| Duration (swelling) | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE |
| Muscle Atrophy | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE |
| Crepitus on motion | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE |
| Flexion Loss | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE |
| Extension Loss | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE |
| Joint Pain | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE |
| Strength | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE | <input type="checkbox"/> NE |
| Joint Total | | | | | | |

Sum of Joint Totals + NE = Non-Evaluable

Global Gait Score
 (NE included in Gait items)

HJHS Total Score =

Swelling

0 - No swelling

1 - Mild

2 - Moderate

3 - Severe

Crepitus on Motion

0 - None

1 - Mild

2 - Severe

Strength (Using The Daniels & Worthingham's scale)

Within available ROM

0 - Holds test position against gravity with maximum resistance (gr.5)

1 - Holds test position against gravity with moderate resistance (but breaks with maximal resistance) (gr.4)

2 - Holds test position with minimal resistance (gr. 3+), or holds test position against gravity (gr.3)

3 - Able to partially complete ROM against gravity (gr.3-/2+), or able to move through ROM gravity eliminated (gr.2), or through partial ROM gravity eliminated (gr.2-)

4 - Trace (gr.1) or no muscle contraction (gr.0)

NE - Non-evaluable

Duration

0 - No swelling or < 6 months

1 - ≥ 6 months

Flexion Loss

0 - < 5°

1 - 5° - 10°

2 - 11° - 20°

3 - > 20°

Global Gait (walking, stairs, running, hopping on 1 leg)

0 - All skills are within normal limits

1 - One skill is not within normal limits

2 - Two skills are not within normal limits

3 - Three skills are not within normal limits

4 - No skills are within normal limits

NE - Non-evaluable

Muscle Atrophy

0 - None

1 - Mild

2 - Severe

Extension loss (from hyperextension)

0 - < 5°

1 - 5° - 10°

2 - 11° - 20°

3 - > 20°

Joint Pain

0 - No pain through active range of motion

1 - No pain through active range; only pain on gentle overpressure or palpation

2 - Pain through active range

NOTE: There is an accompanying instruction manual and worksheets that are required when administering the HJHS

General Comments:

Figure 3: Hemophilia Joint Health Score 2.1.

Current clinical practice requires that the evaluation of our patients be protocolized and objectively quantify the evolutionary follow-up, schedule decisions such as hospital admission or discharge or the need for a specific therapeutic intervention or even the establishment of the degree of disability and the need for care.

Different protocols are used in hemophilia, we will summarize the best known, but all of them include parameters common to the exploration of the locomotor system (Table 3).

| Table 3: Basic explorations to complete the forms recommended by the WFH. | | |
|---|------------------------------------|--|
| | Explorations | Utility |
| 1 | Joint volumes | Inflammation assessment |
| 2 | Muscle volumes | Muscular trophism evaluation |
| 3 | Joint mobility | Ranges of movement (ROM): Flexo-extension and evaluation of contractures |
| 4 | Joint alignment | Assessment of axial deformities |
| 5 | Functional stability | Evaluation of ligament injuries or joint dysfunction due to bone alteration |
| 6 | Joint crepitus | Audible and/or palpable sounds during joint mobility that suggest degenerative processes |
| 7 | Pain | Assessment at rest or during mobility or charging |
| 8 | Muscle balance | Assessment of muscle strength |
| 9 | Orthosis | Verify the need for help to improve pain, mobility or gait |
| 10 | Deambulation (walking, stairs ...) | Assess the possibilities of autonomy in normal gait, stairs, monopod support, jump or race |

One of the first assessments used was that Arnold and Hilgartner [10], which combined clinical and radiographics aspects. However, it was sufficiently useful for to make the hematologist aware that, having lowered the frequency of haemorrhaging, avoiding arthropathy would be the “principle objective”, and a certain phrase started circulating: haemophilia was “an orthopedic disease with a haematological basis”.

The WFH in its recommendations highlights the Gilbert's Core also called WFH Physical Examination and the Hemophilia Joint Health Score (HJHS in its version 2.1), this form is the most commonly used and recommended today for the individual or multiple joint evaluation both in children and adults. The numerical score of each joint can be compared to itself over time to determine if a joint is showing degenerative signs. Other assessments in use are the Colorado protocols [11-17].

The forms that we summarize below are available and can be freely consulted at: [https:// elearning.wfh.org/resource/compendium-of-assessment-tools](https://elearning.wfh.org/resource/compendium-of-assessment-tools) and

www.ipsg.ca. It is important to remember that, regardless of the scale that we are going to use, if at the time of evaluating the patient, there had been any recent bleeding in any of the joints, this should be noted in the observations. That joint is "not testable" since the score of that joint at that time is not valid to assess arthropathy.

The objective of these scales is to describe the baseline situation of the patient in order to be able to carry out an evolutionary control over time. Said basal state should be recovered in case of new bleeding, or at least that should be our goal.

Gilbert's core

Although it has a good correlation with the risk of bleeding and has detected its utility for the measurement of results after physical treatment, is less sensitive than the HJHS and the changes that may affect the patient's clinical situation. The score quantifies 7 concepts: swelling, muscle atrophy, axial deformity, crepitus, range of motion in deficit percentages, flexion contracture and instability. The maximum degree of arthropathy is equivalent to 12 points per joint. The pain score is considered apart (0 to 3 points) [11].

Other scales, less used, are those of Colorado. In its adult version (Colorado Adult Joint Assessment Scale), known by its acronym "CAJAS", it was designed to assess the health of the joints in adults with hemophilia due to the need for validated scales. The CAJAS scale is an evolved version of the Colorado PE-1 and Colorado PE 0.5 scales, developed in turn from the Gilbert scale, trying to improve the limitations it presented. The maximum score is 25 points for the ankles and knees and 23 for the elbows. In the pediatric version (Child PE) the score is 31, ankles and knees and 29 for elbows [15-17].

Hemophilia Joint Health Score (HJHS)

Hemophilia Joint Health Score (HJHS) is probably the most widely used scale today, incorporating items from the Gilbert scale and the Colorado scale. It was originally developed to identify the first signs of joint degeneration in children between 4 and 18 years old, being validated in this population. However, today it is generally used in both children and adults [12-14].

The HJHS 2.1 includes 8 items per joint (i.e. inflammation, duration of inflammation, muscle atrophy, crepitus in movement, loss of flexion, loss of extension, joint pain, and

strength) in addition to comprehensively assessing gait. Each joint has a score of 0-20 points, where 0 implies normality and 20 severe arthropathy. The gait has an evaluation of 0 to 4 points, so that we can give a value per joint or a total score that includes the 6 joints (i.e. both elbows, knees and ankles) plus the gait. The worst possible score for a patient is 124 points (Figure 3).

The second type of scales, those that try to quantify the impact of the pathology on the patient's life, are mostly represented in the bibliography by:

Hemophilia Activities List (HAL adults; PedHAL for children and parents): These are comfortable and quick scales to apply, although they have criticism regarding the reliability and validity of their results, which are still poorly documented in the bibliography. Available at: fh.org/resource/haemophilia-activities-list-hal/

Functional independence measurement for patients with hemophilia (FISH): Scale directed to patients with greater affection. Studies show a good correlation with both the Gilbert scale and the Pettersson and Womac scale. Its internal consistency is good but it is slower to apply than HAL. Available at: <https://elearning.wfh.org/resource/functional-independence-score-in-hemophilia-fish/>

IPAK short form: It is a frequently used questionnaire in the general population that quantifies the level of physical activity in 7 questions, providing three levels of activity, high, moderate and low or inactive. Available at: <https://journals.plos.org/plosone/article/file?type=supplement&id=info:doi/10.1371/journal.pone.0219193.s010>

DIAGNOSTIC IMAGING: CONTROL OF JOINT HEALTH

Conventional radiology

Conventional radiology. In any joint, hemarthrosis can cause structural lesions that start in the soft tissues.

The first manifestation of the image that affects bone tissue is periarticular osteopenia, the epiphysis is progressively affected (due to the increase in vascularization that produces accelerated bone maturation), irregularities of the subchondral bone and progressive destruction of the cartilage with narrowing of the joint space. Additionally, marginal erosions, subchondral cysts, and destruction of the subchondral bone can be seen.

Without adequate treatment of joint injuries, progress is made towards a final stage of hemophilic arthropathy, characterized by deformities and fibrous or bone ankylosis.

The data collected by the Pettersson Scale [18,19] are useful for the classification of hemophilic arthropathy, but ultrasound currently represents the best tool for the detection of early signs of arthropathy.

Magnetic resonance

Magnetic resonance (MRI) is the most sensitive method for detecting early changes in joint structures, whose alteration at the beginning is theoretically reversible. Identifies effusion, synovial membrane, hemosiderin, cartilage, and subchondral bone (erosions and cysts).

MRI constitutes the "gold standard" in diagnostic imaging, however, disadvantages such as the lack of availability in many hemophilia centers, the high cost, the long examination time or the need for sedation in children must be taken into account. Different scales have been published, among which it is worth mentioning the Denver protocol [20-21].

Ultrasound

Ultrasonography (US) allows the identification of the intra-articular effusion without significant differences regarding the use of MRI.

US It is the best technique for assessing vascularization, although this concept is not included in the current parameters for quantifying arthropathy. It presents a good correlation with respect to MRI to assess synovial hypertrophy.

The exploration with US It requires experience (operator dependence) and protocols to quantify effusion, synovial damage, cartilage disorders, cortical erosion, and joint margins.

As advantages we must highlight the ease of access (simple, fast, without sedation) and the low cost. It is used as a first-rate tool in the diagnosis and evolutionary control of acute hemarthrosis and also, with a basic protocol and a simple equipment, in a few minutes it allows determining alterations of the echostructure and objectify, yes or no, joint involvement to later expand the study by specialized personnel and quantify the degree of arthropathy [22].

Currently, the committee of Image Experts works to agree on the protocols. For the evaluation of early signs of arthropathy,

the most widely used score is probably the HEAD-US [23] (Table 4).

| Table 4: Ultrasound examination protocol for early signs of hemophilic arthropathy [23]. | |
|---|--------------|
| <i>Disease activity (sinovitis)</i> | <i>Score</i> |
| Hypertrophic synovium | |
| - Absent/Minimal | 0 |
| - Mild/moderate | 1 |
| - Severe | 2 |
| Disease damage (articular surfaces) | |
| Cartilage | |
| - Normal | 0 |
| - Echotexture abnormalities, focal partial/full-thickness loss of the articular cartilage involving <25% of the target surfaces (*) | 1 |
| - Partial/full-thickness loss of the articular cartilage involving at least ≤50% of the target surface (*) | 2 |
| - Partial/full-thickness loss of the articular cartilage involving >50% of the target surface (*) | 3 |
| - Complete cartilage destruction or absent visualization of the articular cartilage on the target bony surface (*) | 4 |
| Bone | |
| - Normal | 0 |
| - Mild irregularities of the subchondral bone with/without initial osteophytes around the joint | 1 |
| - Deranged subchondral bone with/without erosions and presence of prominent osteophytes around the joint | 2 |
| Total score for each joint | |
| (*) Note: Elbow: anterior aspect of the distal humeral epiphysis; Knee: Femoral trochlea; Ankle: anterior aspect of the talar dome. | |
| It is an additive scale. | |
| The total score represents the sum of the scores for the detected abnormalities. | |
| The range of values ranges from 0 (minimum) to 8 (maximum) for each joint | |

The clinical evaluation, the Hemophilia Joint Health Score (HJHS) and the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) are probably the two fundamental tools for the control of joint health.

CONCLUSION

The prevention and treatment of musculoskeletal injuries in the patient with hemophilia and its consequence, hemophilic arthropathy, remain the main objective of the care of this pathology.

The only way to maintain joint and musculoskeletal health is evolutionary control, for which the unification of criteria in assessment protocols is required.

REFERENCES

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, et al. (2013). Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. *Haemophilia*. 19: e1-e47.
2. Stephensen D, Rodriguez-Merchan EC. (2013). Orthopaedic co-morbidities in the elderly haemophilia population: a review. *Haemophilia*. 19: 166-173.
3. Manco-Johnson MJ, Lundin B, Funk S, Peterfy C, Raunig D, et al. (2017). Effect of late prophylaxis in hemophilia on joint status: a randomized trial. *J Thromb Haemost*. 15: 2115-2124.
4. Aznar JA, Abad-Franch L, Cortina VR, Marco P. (2009). The national registry of haemophilia A and B in Spain results from a census of patients. *Haemophilia*. 15: 1327-1330.
5. Collins PW, Blanchette VS, Fischer K, Bjorkman S, OH M, et al. (2009). Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. *J Thromb Haemost*. 7: 413-420.
6. Valentino LA. (2014). Considerations in individualizing prophylaxis in patients with haemophilia A. *Haemophilia*. 20: 607-615.
7. Iorio A, Keepanasseril A, Foster G, Navarro-Ruan T, McEneny-King A, et al. (2016). Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study Protocol. *JMIR Res Protoc*. 5: e239.
8. Querol F. (2008). Clinical Examination of Haemophilic Arthropathy. Palmero edition, Valencia (Spain).
9. Querol F. (2018). Lesiones musculoesqueléticas en hemofilia: diagnóstico por imagen. Aran ediciones. Madrid (Spain).
10. Arnold WD, Hilgartner MW. (1977). Hemophilic arthropathy: current concepts of pathogenesis and management. *J Bone Joint Surg Am*. 59: 287-305.
11. Gilbert MS. (1993). Prophylaxis: musculoskeletal evaluation. *Semin Haematol*. 30: 3-6.
12. Hilliard P, Funk S, Zourikian N, Bergstrom BM, Bradley CS, et al. (2006). Hemophilia joint health score reliability study. *Haemophilia*. 12: 518-525.
13. Feldman BM, Funk SM, Bergstrom BM, Zourikian N, Hilliard P, et al. (2011). Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. *Arthritis Care Res (Hoboken)*. 63: 223-230.
14. Fischer K, de Kleijn P. (2013). Using the Haemophilia Joint Health Score for assessment of teenagers and young

- adults: exploring reliability and validity. *Haemophilia*. 19: 944-950.
15. Manco-Johnson MJ, Nuss R, Funk S, Murphy J. (2000). Joint evaluation instruments for children and adults with haemophilia. *Haemophilia*. 6: 649-657.
16. Funk SM, Engelen S, Benjamin K, Moshkovich O, Gentile B, et al. (2020). Validity and reliability of the Colorado Adult Joint Assessment Scale in adults with moderate-severe hemophilia A. *J Thromb Haemost*. 18: 285-294.
17. Hacker MR, Funk SM, Manco-Johnson MJ. (2007). The Colorado Haemophilia Paediatric Joint Physical Examination Scale: normal values and interrater reliability. *Haemophilia*. 13: 71-78.
18. Pettersson H, Ahlberg A, Nilsson IM. (1980). A radiologic classification of hemophilic arthropathy. *Clin Orthop Relat Res*. 149: 153-159.
19. Pettersson H. (1993). Radiographic Scores and implications. *Seminars in hematology*. 30: 7-9.
20. Lundin B, Pettersson H, Ljung R. (2004). A new magnetic resonance imaging scoring method for assessment of haemophilic arthropathy. *Haemophilia*. 10: 383-389.
21. Doria AS, Lundin B, Kilcoyne RF, Babyn PS, Miller S, et al. (2005). Reliability of progressive and additive MRI scoring systems for evaluation of haemophilic arthropathy in children: expert MRI Working Group of the International Prophylaxis Study Group. *Haemophilia*. 11: 245-253.
22. Querol F, Rodríguez Merchán EC. (2012). The role of ultrasonography in the diagnosis of the musculoskeletal problems of haemophilia. *Haemophilia*. 18: e215-e226.
23. Martinoli C, Della Casa Alberighi O, Di Minno G, Graziano E, Molinari AC, et al. (2013). Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). *Thromb Haemost*. 109: 1170-1179.